AVTX
AVTX
US05338F3064
Avalo Therapeutics, Inc.
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
732.05M EUR
977.6M EUR
367.84M EUR
336.19M EUR
Enterprise Value
320.22M EUR
892.46M EUR
343.18M EUR
320.73M EUR
Valuation Multiples
Trailing P/E
--
--
--
--
Forward P/E
-5.04x
--
--
--
Price to Sales
12,407.62x
16,569.57x
6,234.62x
5,698.16x
Price to Book
1.61x
2.18x
5.38x
4.05x
EV/Revenue
5,427.4x
15,126.52x
5,816.65x
5,436.03x
EV/EBITDA
-3.51x
--
--
--
Price to FCF (P/FCF)
--
--
--
--
EV/FCF
--
--
--
--
FCF Yield
-3.18%
-6.99%
-16.23%
-12.49%
ende